554 related articles for article (PubMed ID: 28148288)
1. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
2. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
Shao J; Fan W; Ma B; Wu Y
Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
[TBL] [Abstract][Full Text] [Related]
4. ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.
Roy R; Dagher A; Butterfield C; Moses MA
Mol Cancer Res; 2017 Nov; 15(11):1608-1622. PubMed ID: 28765266
[TBL] [Abstract][Full Text] [Related]
5. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
[TBL] [Abstract][Full Text] [Related]
6. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
7. Fascin Is Critical for the Maintenance of Breast Cancer Stem Cell Pool Predominantly via the Activation of the Notch Self-Renewal Pathway.
Barnawi R; Al-Khaldi S; Majed Sleiman G; Sarkar A; Al-Dhfyan A; Al-Mohanna F; Ghebeh H; Al-Alwan M
Stem Cells; 2016 Dec; 34(12):2799-2813. PubMed ID: 27502039
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.
Wang R; Godet I; Yang Y; Salman S; Lu H; Lyu Y; Zuo Q; Wang Y; Zhu Y; Chen C; He J; Gilkes DM; Semenza GL
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33952697
[TBL] [Abstract][Full Text] [Related]
10. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway.
Wang J; Zhang Z; Li R; Mao F; Sun W; Chen J; Zhang H; Bartsch JW; Shu K; Lei T
Biomed Pharmacother; 2018 Jan; 97():1066-1077. PubMed ID: 29136943
[TBL] [Abstract][Full Text] [Related]
11. TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development.
Czerwińska P; Shah PK; Tomczak K; Klimczak M; Mazurek S; Sozańska B; Biecek P; Korski K; Filas V; Mackiewicz A; Andersen JN; Wiznerowicz M
Oncotarget; 2017 Jan; 8(1):863-882. PubMed ID: 27845900
[TBL] [Abstract][Full Text] [Related]
12. ADAM12 induction by Twist1 promotes tumor invasion and metastasis via regulation of invadopodia and focal adhesions.
Eckert MA; Santiago-Medina M; Lwin TM; Kim J; Courtneidge SA; Yang J
J Cell Sci; 2017 Jun; 130(12):2036-2048. PubMed ID: 28468988
[TBL] [Abstract][Full Text] [Related]
13. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
14. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer.
Wei W; Tweardy DJ; Zhang M; Zhang X; Landua J; Petrovic I; Bu W; Roarty K; Hilsenbeck SG; Rosen JM; Lewis MT
Stem Cells; 2014 Oct; 32(10):2571-82. PubMed ID: 24891218
[TBL] [Abstract][Full Text] [Related]
15. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells.
Zhao Z; Lu P; Zhang H; Xu H; Gao N; Li M; Liu C
Breast Cancer Res; 2014 Jul; 16(4):408. PubMed ID: 25056574
[TBL] [Abstract][Full Text] [Related]
16. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype.
Liang YJ; Wang CY; Wang IA; Chen YW; Li LT; Lin CY; Ho MY; Chou TL; Wang YH; Chiou SP; Lin YJ; Yu J
Oncotarget; 2017 Jul; 8(29):47454-47473. PubMed ID: 28537895
[TBL] [Abstract][Full Text] [Related]
17. CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy.
Rostoker R; Ben-Shmuel S; Rashed R; Shen Orr Z; LeRoith D
Breast Cancer Res; 2016 May; 18(1):51. PubMed ID: 27179633
[TBL] [Abstract][Full Text] [Related]
18. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
20. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
